TumCP Cancer Research Results
TumCP, Tumor Cell proliferation: Click to Expand ⟱
| Source: |
| Type: |
Tumor cell proliferation is a key characteristic of cancer. It refers to the rapid and uncontrolled growth of cells that can lead to the formation of tumors.
|
RCC, Renal cell Carcinoma: Click to Expand ⟱
Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms.
The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42).
|
Scientific Papers found: Click to Expand⟱
TumCP↓, TumCMig↓, TumCI↓, TumCG↓, toxicity↓, FTO↑,
| - |
in-vivo, |
RCC, |
A498 |
|
|
|
- |
in-vitro, |
RCC, |
T24/HTB-9 |
|
|
|
- |
NA, |
Bladder, |
5637 |
|
|
|
TRPV1↑, TumCP↓, Casp↑, Apoptosis↑, SIRT1↓, MMP2↓, MMP9↓, TumCMig↓, TumCCA↑, ROS↑, DNAdam↑, PD-L1↑, eff↓,
| - |
vitro+vivo, |
RCC, |
786-O |
|
|
|
- |
in-vitro, |
RCC, |
ACHN |
|
|
|
- |
in-vitro, |
Nor, |
HK-2 |
|
|
|
selectivity↑, TumCP↓, TumCMig↓, TumCI↓, TumCCA↑, TumVol↓, TumW↓, Ki-67↓, MMP9↓, TumAuto↑, LC3B-II↓, Beclin-1↓, p62↑,
TumCG↓, TumCP↓, TumCCA↑, CDK1↓, CycB/CCNB1↓, E-cadherin↝, N-cadherin↝,
AMPK↑, TumCP↓, eff↓, eff↑,
| - |
in-vitro, |
RCC, |
ACHN |
|
|
|
- |
in-vitro, |
RCC, |
786-O |
|
|
|
- |
in-vivo, |
NA, |
NA |
|
|
|
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, NLRP3↓,
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
| - |
in-vivo, |
RCC, |
NA |
|
|
|
- |
in-vivo, |
BCC, |
NA |
|
|
|
HH↓, GLI2↓, Shh↓, Gli1↓, Ki-67↓, TumCP↓,
Showing Research Papers: 1 to 8 of 8
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 2,
Mitochondria & Bioenergetics(tgid=3) ⓘ
MMP↓, 1, mtDam↑, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
AMPK↑, 1, SIRT1↓, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↑, 3, BAX↑, 1, Bcl-2↓, 1, Casp↑, 1, cl‑Casp3↑, 1, TRPV1↑, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
Beclin-1↓, 1, LC3B-II↓, 1, p62↑, 1, TumAuto↑, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
CDK1↓, 1, CycB/CCNB1↓, 1, TumCCA↑, 3,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
EMT↓, 1, Gli1↓, 1, HH↓, 1, Shh↓, 1, TumCG↓, 2,
Migration(tgid=13) ⓘ
E-cadherin↑, 1, E-cadherin↝, 1, FTO↑, 1, GLI2↓, 1, Ki-67↓, 2, MMP2↓, 1, MMP9↓, 3, N-cadherin↝, 1, TumCI↓, 3, TumCMig↓, 5, TumCP↓, 8,
Angiogenesis & Vasculature(tgid=14) ⓘ
VEGF↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
NF-kB↓, 1, PD-L1↑, 1,
Protein Aggregation(tgid=19) ⓘ
NLRP3↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
eff↓, 3, eff↑, 1, selectivity↑, 1,
Clinical Biomarkers(tgid=22) ⓘ
Ki-67↓, 2, PD-L1↑, 1,
Functional Outcomes(tgid=23) ⓘ
toxicity↓, 1, TumVol↓, 1, TumW↓, 1,
Total Targets: 47
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: TumCP, Tumor Cell proliferation
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:24 Cells:% prod#:% Target#:327 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page